Teva Pharmaceutical Industries Ltd. has made an offer to acquire Mylan N.V. in a transaction valued at approximately $40 billion. The proposed combination of Teva and Mylan would create a leading company in the pharmaceutical industry, well positioned to transform the global generics space. The combined company would focus on complex technologies and more durable and sustainable products, in combination with robust capabilities in specialty drug development and commercialization. “Our prop...